Cymabay Therapeutics Incorporated (NASDAQ:CBAY) Could Burn Your Long Portfolio After More Shorts

September 17, 2017 - By test

 Cymabay Therapeutics Incorporated (NASDAQ:CBAY) Could Burn Your Long Portfolio After More Shorts

The stock of Cymabay Therapeutics Incorporated (NASDAQ:CBAY) registered an increase of 14.37% in short interest. CBAY’s total short interest was 1.31M shares in September as published by FINRA. Its up 14.37% from 1.14 million shares, reported previously. With 534,200 shares average volume, it will take short sellers 3 days to cover their CBAY’s short positions. The short interest to Cymabay Therapeutics Incorporated’s float is 5.25%.

The stock increased 2.27% or $0.16 on September 15, reaching $7.2. About 738,984 shares traded or 9.20% up from the average. CymaBay Therapeutics Inc (NASDAQ:CBAY) has risen 69.26% since September 17, 2016 and is uptrending. It has outperformed by 52.56% the S&P500.

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $315.05 million. The Firm is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. It currently has negative earnings. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982.

CymaBay Therapeutics Inc (NASDAQ:CBAY) Ratings Coverage

Among 5 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 13 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Buy” rating by Piper Jaffray on Monday, July 17. As per Wednesday, March 30, the company rating was maintained by H.C. Wainwright. Roth Capital initiated the shares of CBAY in report on Friday, July 1 with “Buy” rating. The firm has “Buy” rating given on Monday, July 17 by H.C. Wainwright. As per Monday, January 30, the company rating was upgraded by H.C. Wainwright. The rating was initiated by Piper Jaffray on Tuesday, July 21 with “Overweight”. As per Tuesday, July 25, the company rating was maintained by Piper Jaffray. The rating was maintained by Piper Jaffray with “Buy” on Monday, September 11. The stock of CymaBay Therapeutics Inc (NASDAQ:CBAY) earned “Neutral” rating by H.C. Wainwright on Wednesday, June 1. On Tuesday, September 8 the stock rating was initiated by H.C. Wainwright with “Buy”.

More notable recent CymaBay Therapeutics Inc (NASDAQ:CBAY) news were published by: Finance.Yahoo.com which released: “Why CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season” on August 09, 2017, also Nasdaq.com with their article: “Implied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options” published on July 13, 2017, Zacks.com published: “Can The Uptrend Continue for Cymabay Therapeutics (CBAY)? February 14, 2017” on February 14, 2017. More interesting news about CymaBay Therapeutics Inc (NASDAQ:CBAY) were released by: Globenewswire.com and their article: “CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of …” published on August 15, 2017 as well as Globenewswire.com‘s news article titled: “CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for …” with publication date: September 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.